| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID715583 | Inhibition of recombinant mouse Shh-N expressed in mouse NIH3T3/Gli-luc cells assessed as inhibition of Gli1 expression after 48 hrs by luciferase reporter gene assay | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715573 | Clearance in dog at 1 mg/kg, iv and 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715580 | Cmax in nu/nu BALB/c mouse at 100 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715571 | AUC (0 to 24 hrs) in rat at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715578 | Antitumor activity in Ptc1+/- p53-/- medulloblastoma allograft model of mouse assessed as tumor growth inhibition at 1 mg/kg, po qd for 14 days relative to control | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID1846000 | Inhibition of hedgehog signalling in mouse NIH3T3 cells cotransfected with Gli luciferase reporter gene assessed as Gli luciferase activity incubated for 48 hrs by Bright-Glo reagent based luciferase assay | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Medulloblastoma drugs in development: Current leads, trials and drawbacks. |
| AID715570 | AUC (0 to 24 hrs) in rat at 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715572 | AUC (0 to 24 hrs) in dog at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715577 | Antitumor activity in Ptc1+/- p53-/- medulloblastoma allograft model of mouse assessed as tumor growth inhibition at 25 mg/kg, po qd for 14 days relative to control | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715568 | Oral bioavailability in rat at 10 mg/kg | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715581 | Solubility of the compound in lapanese pharmacopoeia second fluid at pH 6.8 | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715569 | AUC (0 to 24 hrs) in dog at 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID1234879 | Inhibition of hedgehog signaling pathway in mouse NIH/3T3 cells after 48 hrs by Gli-luciferase reporter gene assay | 2015 | Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
| Synthesis and evaluation of hedgehog signaling inhibitor with novel core system. |
| AID1845999 | Inhibition of Smo D473H mutant (unknown origin) expressed in mouse NIH3T3 cells cotransfected with Gli luciferase reporter gene assessed as Gli luciferase activity incubated for 48 hrs by Bright-Glo reagent based luciferase assay | 2021 | European journal of medicinal chemistry, Apr-05, Volume: 215 | Medulloblastoma drugs in development: Current leads, trials and drawbacks. |
| AID715567 | Oral bioavailability in dog at 10 mg/kg | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715574 | Volume of distribution at steady state in dog at 1 mg/kg, iv and 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715575 | Clearance in rat at 1 mg/kg, iv and 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID715579 | AUC (0 to 24 hrs) in nu/nu BALB/c mouse at 100 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID1234881 | AUC (0 to 8 hrs) in non-fasted mouse at 10 mg/kg, po cassette dosing by LC/MS/MS analysis | 2015 | Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
| Synthesis and evaluation of hedgehog signaling inhibitor with novel core system. |
| AID715576 | Volume of distribution at steady state in rat at 1 mg/kg, iv and 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| AID1234880 | In vivo inhibition of Gli1 mRNA expression in mouse bearing human PAN-04 cells assessed as expression level at 25 mg/kg, po bid after 24 hrs by qPCR analysis relative to control | 2015 | Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15
| Synthesis and evaluation of hedgehog signaling inhibitor with novel core system. |
| AID1345961 | Mouse SMO (Class Frizzled GPCRs) | 2012 | Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
| Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |